Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
NEW YORK, March 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
